Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.56 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27043058 | 0.92 | CA12 (0.47) | CFDBDKRB1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3536911 | 0.88 | LMNA (0.49) | BDKRB1HTTALDH1A1LMNAHSD17B10 | |
| SCHEMBL5321544 | 0.85 | BDKRB1 (0.46) | BDKRB1HTTALDH1A1LMNAHSD17B10 | |
| SCHEMBL3537138 | 0.82 | CFD (0.49) | CFDBDKRB1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3537141 | 0.82 | CFD (0.49) | CFDBDKRB1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL5277198 | 0.81 | BDKRB1 (0.59) | BDKRB1 | |
| SCHEMBL5183278 | 0.81 | BDKRB1 (0.68) | BDKRB1 | |
| SCHEMBL5407348 | 0.80 | BDKRB1 (0.43) | BDKRB1HTTALDH1A1LMNAHSD17B10 | |
| SCHEMBL22772302 | 0.80 | TAS1R3 (0.55) | HTTALDH1A1LMNATAS1R3TAS1R1 | |
| SCHEMBL23363303 | 0.80 | LIPG (0.45) | CFDBDKRB1HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | CFD 4370/4885BDKRB1 386/4885HTT 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.